Pharmaceutical

Biostax and Immgenuity to expedite HIV immunotherapies development

Biostax and Immgenuity have entered into an agreement to expedite the development of new immunotherapeutics to treat HIV and other diseases.

Aug 30, 2023 - 20:00
Biostax and Immgenuity to expedite HIV immunotherapies development
Biostax and Immgenuity have entered into an agreement to expedite the development of new immunotherapeutics to treat HIV and other diseases.
Read the original article

Tags:

Previous Article

FibroGen’s pamrevlumab disappointing results marks second failure in a row

Next Article

EC grants approval to Merck’s Keytruda for gastric cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AltruBio secures $225m for immune checkpoint programme development

AltruBio secures $225m for immune checkpoint programme ...

May 23, 2024

An artist uses the canvas to make sense of her partner’s illness, and her own

An artist uses the canvas to make sense of her partner’...

May 9, 2023

Opioid cravings were reduced by anti-obesity drug in small study

Opioid cravings were reduced by anti-obesity drug in sm...

Feb 17, 2024